Alyse Goldberg, Sandro Graca, Jing Liu, Vibhuti Rao, Selma Feldman Witchel, Alexia Pena, Rong Li, Aya Mousa, Chau Thien Tay, Loyal Pattuwage, Helena Teede, Bulent O Yildiz, Carolyn Ee
This systematic review and meta-analysis evaluated the efficacy of anti-obesity agents for hormonal, reproductive, metabolic, and psychological outcomes in polycystic ovary syndrome (PCOS) to inform the 2023 update of the International Evidence-based Guideline on PCOS. We searched Medline, EMBASE, PsycInfo, and CINAHL until July 2022 with a 10-year limit to focus on newer agents. Eleven trials (545 and 451 participants in intervention and control arms respectively, 12 comparisons) were included. On descriptive analyses, most agents improved anthropometric outcomes; liraglutide, semaglutide and orlistat appeared superior to placebo for anthropometric outcomes...
February 14, 2024: Obesity Reviews